AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33389369
Drug: topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: topical timolol 0.5% (n = 16)
Trial: 33389369
Drug: topical brimonidin
RxNorm normalized name: brimonidine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical brimonidin (n = 15)
Trial: 33389369
Drug: oral acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral acetazolamide 250 mg (n = 14)
Trial: 33389369
Drug: intravenous mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous mannitol (1.5 gr/kg) (n = 16)
Trial: 33389369
Drug: no intraocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no intraocular pressure-lowering medication (n = 13)
Trial: 32131742
Drug: Potentially inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially inappropriate medications (PIMs)
Trial: 33174383
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) 3 times weekly for 8 weeks
Trial: 33174383
Drug: Manual acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual acupuncture (MA) 3 times weekly for 8 weeks
Trial: 33174383
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture (SA) 3 times weekly for 8 weeks
Trial: 33351101
Drug: VKA regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VKA regimen with triple-Antithrombotic therapy
Trial: 32706640
Drug: Postradiation chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine)
Trial: 35751032
Drug: Resistance 'exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance 'exercise snacks' performed once daily (n=9)
Trial: 35751032
Drug: Resistance 'exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance 'exercise snacks' performed twice daily (n=10)
Trial: 35751032
Drug: Resistance 'exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance 'exercise snacks' performed thrice daily (n=9)
Trial: 36364828
Drug: Food for
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food for special medical purposes composed of omega‐3 fatty acids (500 mg), leucine (2.5 g), and probiotic Lactobacillus paracasei PS23
Trial: 35126899
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (supplemented with Western medical treatment)
Trial: 35132421
Drug: Oral camostat
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral camostat mesylate, 200 mg po four times a day for 7 days
Trial: 32406224
Drug: Single rehabilitative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single rehabilitative treatment (ST)
Trial: 32406224
Drug: Group rehabilitative
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group rehabilitative treatment (GT)
Trial: 33170444
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - 10 individual, weekly sessions preoperative
Trial: 33556230
Drug: Atezolizumab and
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab and bevacizumab combination
Trial: 36380312
Drug: MEDI3902 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI3902 1500 mg (single intravenous dose)
Trial: 36380312
Drug: MEDI3902 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI3902 1500 mg
Trial: 34331755
Drug: Osteopathic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manual therapy (OMT)
Trial: 34220324
Drug: Low bilirubin
RxNorm normalized name: bilirubin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low bilirubin group (serum bilirubin≤9.7umol/L, n=753)
Trial: 34220324
Drug: High bilirubin
RxNorm normalized name: bilirubin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High bilirubin group (serum bilirubin>9.7umol/L, n=739)
Trial: 32709657
Drug: Individualised, pharmacist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised, pharmacist led support service focusing on medication adherence and physical comorbidity management.
Trial: 35592991
Drug: Online therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online therapy management system (TMS) with wearable auricular vagus nerve stimulation device
Trial: 33040814
Drug: Physiological seawater
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological seawater nasal irrigation combined with oral desloratadine citrate disodium
Trial: 33040814
Drug: Oral desloratadine
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral desloratadine citrate disodium
Trial: 33599087
Drug: Adapted Dialectical
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted Dialectical Behaviour Therapy (aDBT-ID)
Trial: 32899022
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment arm (vitamin K2 isoform 360 mcg 3 times weekly for 18 months)
Trial: 32985288
Drug: Chamomile gel
RxNorm normalized name: Chamomile
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile gel (8.35%)
Trial: 32926847
Drug: Text parsing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Text parsing tool for identifying poor medication adherence
Trial: 32926847
Drug: Self-reported medication
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported medication adherence assessment
Trial: 35192860
Drug: 75-mg clopidogrel
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-mg clopidogrel daily (n=80)
Trial: 35192860
Drug: 3.75-mg prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75-mg prasugrel daily (n=84)
Trial: 33925704
Drug: Cooked ham
RxNorm normalized name: egg shell, cooked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooked ham enriched with antioxidants (100 g/d)
Trial: 33691439
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (EA + dyclonine hydrochloride)
Trial: 33798487
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of moxidectin
Trial: 33798487
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of moxidectin
Trial: 33798487
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of moxidectin
Trial: 33798487
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of moxidectin
Trial: 33798487
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of moxidectin
Trial: 33798487
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg of moxidectin
Trial: 36864979
Drug: Allopurinol 300
RxNorm normalized name: allopurinol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg twice daily
Trial: 35689370
Drug: Focused Extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Focused Extracorporeal Shock Wave Therapy (fESWT) at the lumbar and sacral spine (0.15 mJ/mm², 1000 pulses, 4 Hz)
Trial: 34534863
Drug: Injection extended-release
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection extended-release naltrexone (XR-NTX), delivered approximately every 28 days
Trial: 34534863
Drug: Daily sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sublingual buprenorphine-naloxone (BUP-NX)
Trial: 34534863
Drug: Estimated individualized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estimated individualized treatment rule for OUD
Trial: 32487150
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide (500 mg thrice daily)
Trial: 32487150
Drug: Naldemedine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naldemedine (0.2 mg once daily)
Trial: 35488084
Drug: lenrispodun 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenrispodun 1.0 mg
Trial: 35488084
Drug: lenrispodun 10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenrispodun 10.0 mg
Trial: 32784346
Drug: IV vortioxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV vortioxetine 25 mg plus daily oral vortioxetine 10 mg
Trial: 32784346
Drug: IV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo plus daily oral placebo
Trial: 36379827
Drug: Modified Vocal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Vocal Function Exercises with reduced requirement for maximally sustained phonation (midpoint group MG)
Trial: 33648515
Drug: Empagliflozin (EMPA)
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin (EMPA) 10 mg/day in humans
Trial: 33648515
Drug: Empagliflozin (EMPA)
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin (EMPA) 30 mg/kg in mice
Trial: 32894959
Drug: Pectoral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectoral nerve block with 30 ml ropivacaine 0.375% (Pecs group)
Trial: 32894959
Drug: Thoracic paravertebral
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic paravertebral block with 20 ml ropivacaine 0.5% (TPVB group)
Trial: 32087795
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate 300 mg once a day
Trial: 33735884
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 and carboplatin AUC 5 every 3 weeks
Trial: 33735884
Drug: Paclitaxel 80
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m2 on day 1, day 8, and day 15 with carboplatin AUC 5 every 4 weeks for 4 cycles
Trial: 38188539
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.5 mg/kg)
Trial: 32603389
Drug: CO2 laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 laser ablative fractional resurfacing (AFR) followed by ALA photodynamic therapy (PDT)
Trial: 32603389
Drug: ALA photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA photodynamic therapy (PDT) alone
Trial: 34718434
Drug: Tocilizumab weekly
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab weekly (TCZ QW)
Trial: 32393496
Drug: 3,600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,600 mg MHAA4549A + OTV
Trial: 32393496
Drug: 8,400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8,400 mg MHAA4549A + OTV
Trial: 35688490
Drug: Micronised progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised progesterone (Utrogestan® 200mg) + transdermal oestradiol (Evorel® Patches 50mcg/day)
Trial: 35688490
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (Provera® 10mg) + transdermal oestradiol (Evorel® Patches 50mcg/day)
Trial: 33472681
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (single infusion) plus standard of care (SOC)
Trial: 32125903
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride extended-release capsules (MPH-MLR) 10 mg once daily, with weekly adjustments up to 40 mg.
Trial: 32125903
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride extended-release capsules (MPH-MLR)
Trial: 32507386
Drug: Single-infusion donor-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-infusion donor-derived anti-CD19 CAR T cells
Trial: 35287091
Drug: Droperidol 5
RxNorm normalized name: droPERidol 5 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 5 mg/midazolam 5 mg IM
Trial: 35287091
Drug: Haloperidol 5
RxNorm normalized name: haloperidol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 5 mg/lorazepam 2 mg IM
Trial: 35939501
Drug: UV-4 hydrochloride
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: UV-4 hydrochloride (UV-4B) at doses of 3, 10, 30, 90, 180, 360, 720, or 1000 mg
Trial: 33148955
Drug: 1-g intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g intravenous (IV) TXA prior to incision (single-dose IV group)
Trial: 33148955
Drug: 1-g IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g IV TXA prior to incision followed by 1-g IV TXA after arthrotomy wound closure (double-dose IV group)
Trial: 33148955
Drug: 1-g IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g IV TXA prior to incision and 1-g intraoperative topical TXA (combined IV and topical group)
Trial: 33148955
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses totaling 1,950-mg oral TXA (multidose oral group)
Trial: 35120150
Drug: Formula supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula supplementation (up to 59 milliliters administered daily for 30 days)
Trial: 35564709
Drug: Blueberry juice
RxNorm normalized name: lowbush blueberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry juice (60 mL per day for 20 days)
Trial: 35564709
Drug: Placebo (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (60 mL per day for 20 days)
Trial: 33803802
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of oat oil with a high concentration (40%) of polar lipids (PLH)
Trial: 33803802
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of rapeseed oil (RSO)
Trial: 33803802
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of oat oil with a low concentration (4%) of polar lipids (PLL)
Trial: 33099836
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of FCO2 and FRF
Trial: 32882447
Drug: Monthly aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly aflibercept injections (2 mg)
Trial: 32882447
Drug: Quarterly aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Quarterly aflibercept injections (2 mg)
Trial: 32882447
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (monthly and quarterly aflibercept injections)
Trial: 36107843
Drug: OC‐01 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC‐01 0.03 mg BID
Trial: 36107843
Drug: OC‐01 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC‐01 0.06 mg BID
Trial: 36107843
Drug: Vehicle nasal
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle nasal spray BID
Trial: 39429046
Drug: Dietetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietetic treatment
Trial: 34635804
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) treatment once a week for four weeks with 3000 impulses each
Trial: 34635804
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with air-filled microspheres
Trial: 35387483
Drug: Ticagrelor 60
RxNorm normalized name: ticagrelor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 60 mg BD
Trial: 35387483
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg OD
Trial: 32879783
Drug: Levosulpiride (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosulpiride (25 mg orally TID for 7 days)
Trial: 32879783
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose pill, orally TID for 7 days)
Trial: 35093013
Drug: Atogepant 30
RxNorm normalized name: atogepant 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant 30 mg
Trial: 32512353
Drug: Adjunctive group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive group-based psychosocial intervention (12 weekly sessions and 3 monthly booster sessions)
Trial: 32970235
Drug: Other exposure
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other exposure status (less nutritious supplement or improved nutrition at other ages)
Trial: 36384493
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy combined with NBP treatment (NBP 200 mg, three times per day for 24 weeks)
Trial: 33746857
Drug: Modular Approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modular Approach to Therapy for Children (MATCH)
Trial: 35199250
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green injection with the da Vinci Xi‐equipped Firefly system
Trial: 35123236
Drug: Push-pull with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Push-pull with 60 mL syringe
Trial: 35123236
Drug: Push-pull with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Push-pull with 10 mL syringe
Trial: 36052536
Drug: Enfortumab vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enfortumab vedotin (EV) 1.25 mg/kg on Days 1, 8, and 15 for 28-day cycles
Trial: 36052536
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (SC; docetaxel or paclitaxel) on Day 1 of each 21-day cycle
Trial: 34688923
Drug: Present-centered group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present-centered group therapy (control)
Trial: 96008295
Drug: Interferon-alpha (IFN-alpha)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN-alpha) at a dose of 5MU daily or 10 MU three times a week for 3 to 6 months
Trial: 96008295
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies including interferon alpha with Ara-AMP, acyclovir, didoxynucleoside or interferon-gamma
Trial: 35715644
Drug: Astodrimer sodium
RxNorm normalized name: Astodrimer
DrugBank: Astodrimer (DB11854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astodrimer sodium nasal spray (1%)
Trial: 33426570
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel (HAG)
Trial: 34352588
Drug: EP prenylflavonoid
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP prenylflavonoid extract (740 mg daily)
Trial: 36379585
Drug: Add-on imeglimin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on imeglimin 1000 mg two times per day
Trial: 36379585
Drug: Metformin dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin dose escalation
Trial: 33300818
Drug: Montelukast formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast formulations